Effects of Epothilone A in Combination with the Antidiabetic Drugs Metformin and Sitagliptin in HepG2 Human Hepatocellular Cancer Cells: Role of Transcriptional Factors NF-κB and p53 |
Rogalska, Aneta
(Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz)
Sliwinska, Agnieszka (Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Lodz) Kasznicki, Jacek (Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Lodz) Drzewoski, Jozef (Department of Internal Medicine, Diabetology and Clinical Pharmacology, Medical University of Lodz) Marczak, Agnieszka (Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz) |
1 | Azlin AH, Looi LM, Cheah PL (2014). Tissue microarray immunohistochemical profiles of p53 and pRB in hepatocellular carcinoma and hepatoblastoma. Asian Pac J Cancer Prev, 15, 3959-63. DOI |
2 | Baldwin AS (2012). Regulation of cell death and autophagy by IKK and NF-kappaB: critical mechanisms in immune function and cancer. Immunological Rev, 246, 327-45. DOI |
3 | Ben Sahra I, Laurent K, Giuliano S, et al (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res, 70, 2465-75. DOI |
4 | Bost F, Sahra IB, Le Marchand-Brustel Y, et al (2012). Metformin and cancer therapy. Curr Opin Oncol, 24, 103-8. DOI |
5 | Cai X, Hu X, Cai B, et al (2013). Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo. Oncol Rep, 30, 2449-57. DOI |
6 | Carmichael J, DeGraff WG, Gazdar AF, et al (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res, 47, 936-42. |
7 | Chang AY, Wang M (2013). In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs, 24, 251-9. DOI |
8 | Chaudhary SC, Kurundkar D, Elmets CA, et al (2012). Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol, 88, 1149-56. DOI |
9 | Chen HP, Shieh JJ, Chang CC, et al (2013). Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut, 62, 606-15. DOI |
10 | Chen TM, Lin CC, Huang PT, et al (2011). Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol, 26, 858-65. DOI |
11 | Chiang GG, Abraham RT (2007). Targeting the mTOR signaling network in cancer. Trends Mol Med, 13, 433-42. DOI |
12 | Davoudi Z, Akbarzadeh A, Rahmatiyamchi M, et al (2014). Molecular target therapy of AKT and NF- signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cells. asian pac j cancer prev, 15, 4353-8. DOI |
13 | Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W, et al (2013). The effects of metformin on ovarian cancer: a systematic review. International J Gynecological Cancer, 23, 1544-51. DOI |
14 | Ganesan C, Obulareddy SJ, Fischer JH, et al (2014). Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors. am j clinical oncol. |
15 | Giannakakou P, Nakano M, Nicolaou KC, et al (2002). Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA, 99, 10855-60. DOI |
16 | Hadad SM, Hardie DG, Appleyard V, Thompson AM (2014). Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol, 16, 746-52. DOI |
17 | Hammer S, Sommer A, Fichtner I, et al (2010). Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin Cancer Res, 16, 1452-65. DOI |
18 | Harris K, Smith L (2013). Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother, 47, 1348-52. DOI |
19 | Hofer A, Noe N, Tischner C, et al (2014). Defining the action spectrum of potential PGC-1alpha activators on a mitochondrial and cellular level in vivo. Human molecular genetics. |
20 | Hayden MS, Ghosh S (2012). NF-kappaB, the first quartercentury: remarkable progress and outstanding questions. Genes Development, 26, 203-34. DOI |
21 | Huang Y, Fan W (2002). IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Molecular Pharmacol, 61, 105-13. DOI |
22 | Ismail S, Mayah W, Battia HE, et al (2015). Plasma nuclear factor kappa B and serum peroxiredoxin 3 in early diagnosis of hepatocellular carcinoma. Asian Pac J Cancer Prev, 16, 1657-63. DOI |
23 | Kapahi P, Takahashi T, Natoli G, et al (2000). Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biological Chemistry, 275, 36062-6. DOI |
24 | Kasznicki J, Sliwinska A, Drzewoski J (2014). Metformin in cancer prevention and therapy. Ann Transl Med, 2, 57. |
25 | Lee SH, Son SM, Son DJ, et al (2007). Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factorkappaB/IkappaB kinase signal pathway. Molecular Cancer Therapeutics, 6, 2786-97. DOI |
26 | Lenski M, Kazakov A, Marx N, et al (2011). Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Molecular Cellular Cardiology, 51, 906-18. DOI |
27 | Loong HH, Yeo W (2014). Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther, 7, 575-85. |
28 | Mok TS, Choi E, Yau D, et al (2006). Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncol, 71, 292-6. DOI |
29 | Madan E, Gogna R, Bhatt M, et al (2011). Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget, 2, 948-57. DOI |
30 | Miyoshi H, Kato K, Iwama H, et al (2014). Effect of the antidiabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol, 45, 322-32. DOI |
31 | Otte A, Rauprich F, Hillemanns P, et al (2014). In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model. Orphanet J Rare Dis, 9, 126. DOI |
32 | Patel S, Singh N, Kumar L (2015). Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells. Asian Pacific J Cancer Prev, 16, 6973-9. DOI |
33 | Rengarajan T, Nandakumar N, Rajendran P, et al (2014). D-pinitol promotes apoptosis in MCF-7 cells via induction of p53 and Bax and inhibition of Bcl-2 and NF-kappaB. Asian Pac J Cancer Prev, 15, 1757-62. DOI |
34 | Rogalska A, Gajek A, Marczak A (2014). Epothilone B induces extrinsic pathway of apoptosis in human SKOV-3 ovarian cancer cells. Toxicol In Vitro, 28, 675-83. DOI |
35 | Rogalska A, Marczak A, Gajek A, et al (2013a). Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol In Vitro, 27, 239-49. DOI |
36 | Rogalska A, Szula E, Gajek A, et al (2013b). Activation of apoptotic pathway in normal, cancer ovarian cells by epothilone B. Environ Toxicol Pharmacol, 36, 600-10. DOI |
37 | Tan HK, Moad AI, Tan ML (2014). The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals. Asian Pac J Cancer Prev, 15, 6463-75. DOI |
38 | Saito T, Chiba T, Yuki K, et al (2013). Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PloS one, 8, 70010. DOI |
39 | Sangle GV, Lauffer LM, Grieco A, et al (2012). Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinol, 153, 564-73. DOI |
40 | Sliwinska A, Rogalska A, Marczak A, et al (2015). Metformin, but not sitagliptin, enhances WP 631-induced apoptotic HepG2 cell death. Toxicol In Vitro, 29, 1116-23. DOI |
41 | Ueda Y, Richmond A (2006). NF-kappaB activation in melanoma. Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society, 19, 112-24. DOI |
42 | Wang CH, Wey KC, Mo LR, et al (2015). Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev, 16, 3595-604. DOI |
43 | Wardle EN (2001). Nuclear factor kappaB for the nephrologist. Nephrol Dial Transplant, 16, 1764-8. DOI |
44 | Winsel S, Sommer A, Eschenbrenner J, et al (2011). Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells. PloS one, 6, 19273. DOI |
45 | Woudenberg-Vrenken TE, Conde de la Rosa L, Buist-Homan M, et al (2013). Metformin protects rat hepatocytes against bile acid-induced apoptosis. PloS one, 8, 71773. DOI |
46 | Zheng L, Yang W, Wu F, et al (2013). Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clinical Cancer Res, 19, 5372-80. DOI |
47 | Yi G, He Z, Zhou X, et al (2013). Low concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. Int J Oncol, 43, 1503-10. DOI |
48 | Zhang H, An F, Tang L, et al (2014). Multiple effects of a novel epothilone analog on cellular processes and signaling pathways regulated by Rac1 GTPase in the human breast cancer cells. Korean J Physiol Pharmacol, 18, 109-20. DOI |
49 | Zhang ZJ, Li S (2014). The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 16, 707-10. DOI |
50 | Zhou Q, Wong CH, Lau CP, et al (2013). Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol, 2013, 103830. |
51 | Zhuang Y, Miskimins WK (2008a). Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Molecular Signal, 3, 18. DOI |
52 | Zhuang Y, Miskimins WK (2008b). Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal, 3, 18. DOI |
53 | Zuco V, Zunino F (2008). Cyclic pifithrin-alpha sensitizes wild type p53 tumor cells to antimicrotubule agent-induced apoptosis. Neoplasia, 10, 587-96. DOI |
54 | Aoki M, Nata T, Morishita R, et al (2001). Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension, 38, 48-55. DOI |
55 | Alberti C (2013). Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma. Eur Rev Med Pharmacological Sci, 17, 1658-64. |
56 | Aldea M, Craciun L, Tomuleasa C, et al (2014). Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery. Tumour Biol, 35, 5101-10. DOI |
57 | An F, Zhao WJ, Tang L, et al (2015). Concentration-dependent differential effects of an epothilone analog on cell cycle and p53 signaling. Oncol Rep. |